Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070156 | 0.91 | LTA4H (0.56) | LTA4HNPC1RAB9ASMN1; SMN2NPY5R | |
| SCHEMBL5360486 | 0.86 | KMT2A (0.54) | LTA4HRAB9ASMN1; SMN2MAOBALOX5 | |
| SCHEMBL5884767 | 0.85 | LTA4H (0.58) | LTA4HNPC1RAB9ASMN1; SMN2NPY5R | |
| SCHEMBL10603321 | 0.83 | LTA4H (0.62) | LTA4HNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL7444074 | 0.83 | LTA4H (0.62) | LTA4HNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL31579489 | 0.82 | LTA4H (0.60) | LTA4HNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL5377231 | 0.82 | HPGD (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2840120 | 0.81 | LTA4H (0.59) | LTA4HNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL6266373 | 0.81 | LTA4H (0.59) | LTA4HNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL11606393 | 0.80 | LMNA (0.66) | LTA4HRAB9ASMN1; SMN2MAOBALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321056-B2 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321056-B2 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070066683-A1 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066683-A1 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066683-A1 | Selective peroxisome proliferator activated receptor modulators | PPARG, PPARD, PPARA | LTA4H 2093/4885NPC1 473/4885RAB9A 3614/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | LTA4H 2072/4885NPC1 1429/4885RAB9A 3987/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | LTA4H 2124/4885NPC1 1791/4885RAB9A 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.